parallax background

• SUPERIOR GENE DELIVERY TECHNOLOGY
• MINIMAL IMMUNE RESPONSE
• REPEAT DOSING

Saving children's lives,
one genetic disease at a time.


Our mission

Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, our goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires.

We are committed to every child and family who suffers from a genetic disorder. Our mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.

A revolutionary approach to gene therapy

Chameleon's patented EVADER platform technology is a brand-new approach to gene therapy that overcomes existing treatment barriers. EVADER technology effectively cloaks the current standard of care treatment capsid by:
  • Shielding the capsid from antibodies
  • Reducing antibody production
  • Masking foreign proteins to increase tolerance

Our Vision



While our technology is still in the research stage, we have promising data and positive early in vivo and in vitro results. Our hope is that Chameleon treatments will effectively address these conditions within the next five years.



Our Vision

While our technology is still in the research stage, we have promising data and positive early in vivo and in vitro results. We hope our treatment will effectively address these conditions within the next five years.


Advantages of Our Treatment Approach

RESISTANCE TO PRE-EXISTING ANTIBODIES
10X
LOWER DOSE
ACCURATE TARGET SPECIFICITY
REPEAT DOSING

Contact Us

Stay informed of our progress:
Currently raising a seed round:
Chameleon is interested in forming collaborations:
Contact us to learn more: